Minnelide, a novel drug for pancreatic and liver cancer

Sulagna Banerjee; Ashok Saluja

doi:10.1016/j.pan.2015.05.472

Minnelide, a novel drug for pancreatic and liver cancer

Sulagna Banerjee
, Ashok Saluja

Research output: Contribution to journal › Review article › peer-review

54 Scopus citations

Abstract

BACKGROUND: Pancreatic cancer is the 10th leading cause of all new cancer cases for men and the fourth leading cause of death across genders, having very poor prognosis and survival rates. The current standard of care Gemcitabine fails to add any survival benefit for this disease (www.cancer.gov). Though the incidence of pancreatic cancer is found to be higher in developed countries, the aggressive biology of the cancer, its high rate of recurrence and chemo-resistance make it a formidable disease in all parts of the globe. Hepatocellular carcinoma (HCC) or liver cancer, on the other hand affects almost 750,000 people world wide with 84% of the cases coming from underdeveloped or developing countries

RESULTS: Our studies show that Minnelide, a water soluble pro-drug of triptolide (active compound from a chinese herb) is very effective against a number of malignant diseases.

CONCLUSION: The current study discusses the efficacy of this compound in pancreatic and liver cancer.

Original language	English (US)
Pages (from-to)	S39-S43
Journal	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.pan.2015.05.472 https://doi.org/10.1016/j.pan.2015.05.472
State	Published - Jul 1 2015

Bibliographical note

Publisher Copyright:
© 2015 IAP and EPC

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Animal models
Hepatocellular carcinoma
Minnelide
Pancreatic cancer
Translational study
Triptolide

Publisher link

Find It

Find It at U of M Libraries

Cite this

@article{e9074725d5e547d4b655154aabd9a79a,

title = "Minnelide, a novel drug for pancreatic and liver cancer",

abstract = "BACKGROUND: Pancreatic cancer is the 10th leading cause of all new cancer cases for men and the fourth leading cause of death across genders, having very poor prognosis and survival rates. The current standard of care Gemcitabine fails to add any survival benefit for this disease (www.cancer.gov). Though the incidence of pancreatic cancer is found to be higher in developed countries, the aggressive biology of the cancer, its high rate of recurrence and chemo-resistance make it a formidable disease in all parts of the globe. Hepatocellular carcinoma (HCC) or liver cancer, on the other hand affects almost 750,000 people world wide with 84\% of the cases coming from underdeveloped or developing countriesRESULTS: Our studies show that Minnelide, a water soluble pro-drug of triptolide (active compound from a chinese herb) is very effective against a number of malignant diseases.CONCLUSION: The current study discusses the efficacy of this compound in pancreatic and liver cancer.",

keywords = "Animal models, Hepatocellular carcinoma, Minnelide, Pancreatic cancer, Translational study, Triptolide",

author = "Sulagna Banerjee and Ashok Saluja",

note = "Publisher Copyright: {\textcopyright} 2015 IAP and EPC",

year = "2015",

month = jul,

day = "1",

doi = "10.1016/j.pan.2015.05.472",

language = "English (US)",

volume = "15",

pages = "S39--S43",

journal = "Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]",

issn = "1424-3903",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Minnelide, a novel drug for pancreatic and liver cancer

AU - Banerjee, Sulagna

AU - Saluja, Ashok

PY - 2015/7/1

Y1 - 2015/7/1

N2 - BACKGROUND: Pancreatic cancer is the 10th leading cause of all new cancer cases for men and the fourth leading cause of death across genders, having very poor prognosis and survival rates. The current standard of care Gemcitabine fails to add any survival benefit for this disease (www.cancer.gov). Though the incidence of pancreatic cancer is found to be higher in developed countries, the aggressive biology of the cancer, its high rate of recurrence and chemo-resistance make it a formidable disease in all parts of the globe. Hepatocellular carcinoma (HCC) or liver cancer, on the other hand affects almost 750,000 people world wide with 84% of the cases coming from underdeveloped or developing countriesRESULTS: Our studies show that Minnelide, a water soluble pro-drug of triptolide (active compound from a chinese herb) is very effective against a number of malignant diseases.CONCLUSION: The current study discusses the efficacy of this compound in pancreatic and liver cancer.

AB - BACKGROUND: Pancreatic cancer is the 10th leading cause of all new cancer cases for men and the fourth leading cause of death across genders, having very poor prognosis and survival rates. The current standard of care Gemcitabine fails to add any survival benefit for this disease (www.cancer.gov). Though the incidence of pancreatic cancer is found to be higher in developed countries, the aggressive biology of the cancer, its high rate of recurrence and chemo-resistance make it a formidable disease in all parts of the globe. Hepatocellular carcinoma (HCC) or liver cancer, on the other hand affects almost 750,000 people world wide with 84% of the cases coming from underdeveloped or developing countriesRESULTS: Our studies show that Minnelide, a water soluble pro-drug of triptolide (active compound from a chinese herb) is very effective against a number of malignant diseases.CONCLUSION: The current study discusses the efficacy of this compound in pancreatic and liver cancer.

KW - Animal models

KW - Hepatocellular carcinoma

KW - Minnelide

KW - Pancreatic cancer

KW - Translational study

KW - Triptolide

UR - https://www.scopus.com/pages/publications/84932150692

UR - https://www.scopus.com/pages/publications/84932150692#tab=citedBy

U2 - 10.1016/j.pan.2015.05.472

DO - 10.1016/j.pan.2015.05.472

M3 - Review article

C2 - 26122306

AN - SCOPUS:84932150692

SN - 1424-3903

VL - 15

SP - S39-S43

JO - Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

JF - Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

IS - 4

ER -

Minnelide, a novel drug for pancreatic and liver cancer

Abstract

Bibliographical note

UN SDGs

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this